ArticleJournal of nanobiotechnology2025
pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biotransformation of Maclekarpine E in Rats: CYP2C19-Mediated Metabolism, Fecal Enrichment, and Network Pharmacology-Based Anti-Ulcerative Colitis Prediction.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAlthough therapeutic options for inflammatory bowel disease (IBD) have advanced, many patients still experience suboptimal clinical response, systemic side effects, or difficulty maintaining long-term treatment adherence. Hydrogen sulfide (H₂S), an endogenous gasotransmitter with potent anti-inflammatory and mucosal-protective properties, has shown promise as a therapeutic agent for IBD. However, clinical application has been constrained by its instability in low pH and the need for parenteral administration.
resultsHere, we report the first orally administered, pH-responsive liposomal formulation of the H₂S donor GYY4137, specifically designed for colon-targeted delivery. This system, termed oral hydrogen sulfide donor-loaded liposome (Oral H₂S lipo), employs a pH-sensitive Eudragit S100 coating that forms protective aggregates under acidic gastric conditions (pH 2) to shield the liposomes and suppress premature H₂S release. In this environment, Oral H₂S lipo limited cumulative release of H
conclusionsThese findings demonstrate that Oral H₂S lipo enables effective, site-specific delivery of H₂S to inflamed colonic tissue, offering a clinically relevant platform to overcome limitations of conventional H₂S donor therapies in IBD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.